

Clinical case discussion

*DAA-Resistance from a Clinical Perspective,
Amsterdam, 4 December 2015*

Christoph Sarrazin
Goethe-University Hospital
Frankfurt am Main
Germany



Disclosures

Consultancies / Advisory boards:

Abbott, Abbvie, BMS, Gilead, Janssen, Merck/MSD, Roche

Research support:

Abbott, Gilead, Janssen, Qiagen, Roche, Siemens

Speaker:

Abbott, Abbvie, Achillion, BMS, Gilead, Janssen, Merck/MSD, Qiagen, Roche, Siemens

Patient case

Re-treatment of DAA-Failure

***1954, male, 82kg**

Chronic Hepatitis C

- First diagnosed 1993
- Genotype 4
- IL28B TT
- Viral load 1.32 Mill. IU/ml
- Liver function clinical comp. cirrhosis since 2010, 21 kPa
MELD 8, Child A
- Therapy IFN 1998,
PEG/R 2011/12,
SOF/P/R 3/14-6/14
- Complications no ascites, no bleeding of EV, no HRS
HCC in liver segment 3, local resection 2010
- Medication: none

August 2014

- **Referred for evaluation for antiviral therapy to University Hospital Frankfurt**

Patient case

Re-treatment of DAA-Failure

***1954, male, 82kg**

HCV GT 4, comp. cirrhosis, past HCC, Child A
Failure to IFN, P/R and SOF+P/R

Parameter	Baseline	
Hb	13.2	
Thrombocytes	104	
ALT	49	
AST	36	
Bili	1.2 mg/dl	
Albumin	4.5 g/dl	
INR	1.2	
Fibroscan	21 kPa	
Ascites	-	
AFP	14.5	
HCV RNA	1.3 Mill	

Patient case

Re-treatment of DAA-Failure

***1954, male, 82kg**

HCV GT 4, comp. cirrhosis, past HCC, Child A
Failure to IFN, P/R and SOF+P/R



Known old
echinococcus cyst

No HCC recidive or
new nodules

Patient case

Re-treatment of DAA-Failure

***1954, male, 82kg**

HCV GT 4, comp. cirrhosis, past HCC, Child A
Failure to IFN, P/R and SOF+P/R

Resistance analysis Frankfurt:

HCV GT by sequencing	4d	4r with reduced LDV efficacy, failures to 2D mainly 4d
NS3 protease	T122S	WT, no effect on SMV
NS5A	T58P	unclear, not tested for GT4, for GT1 RAVs at pos. 58 assoc. with resistance
NS5B	none	

Patient case

Re-treatment of DAA-Failure

***1954, male, 82kg**

HCV GT 4, comp. cirrhosis, past HCC, Child A
Failure to IFN, P/R and SOF+P/R

RAVs: no NS3 RAVs, unclear importance of NS5A T58P

Treatment:

Simeprevir	150mg /die
Sofosbuvir	400mg /die
Ribavirin	1200mg /die

Duration: 12 weeks

Patient case

Re-treatment of DAA-Failure

***1954, male, 82kg**

HCV GT 4, comp. cirrhosis, past HCC, Child A

► Re-treatment with SMV/SOF + RBV

Parameter	Baseline	TW4
Hb	13.2	12.9
Thrombocytes	104	129
ALT	49	16
AST	36	19
Bili	1.2 mg/dl	2.8
Albumin	4.5 g/dl	4.5
INR	1.2	1.1
Fibroscan	21 kPa	
Ascites	-	-
AFP	14.5	22.7
HCV RNA	1.3 Mill	neg. (<15)

Patient case

HCV suppression and clinical improvement in Child A case

***1954, male, 82kg**

HCV GT 4, comp. cirrhosis, past HCC, Child A

► Re-treatment with SMV/SOF + RBV

Parameter	Baseline	TW4	TW8	TW12	FU12
Hb	13.2	12.9	12.3	11.8	12.6
Thrombocytes	104	129	156	167	137
ALT	49	16	16	17	15
AST	36	19	23	23	25
Bili	1.2 mg/dl	2.8	2.5	2.8	0.8
Albumin	4.5 g/dl	4.5	4.2	4.4	4.5
INR	1.2	1.1	1.1	1.1	1.1
Fibroscan	21 kPa				17
Ascites	-	-	-	-	-
AFP	14.5	22.7	36.2	17.1	17.0
HCV RNA	1.3 Mill	neg. (<15)	neg	neg	Neg

Patient case

HCV suppression and clinical improvement in Child A case

***1954, male, 82kg**

HCV GT 4, comp. cirrhosis, past HCC, Child A

▶ SVR after re-treatment with SMV/SOF + RBV

Long term follow-up 10/2015

- Comp. cirrhosis, Child A
- HCV RNA negative
- Two new nodules 10 and 12mm in MRT scan
- Control MRI in 3 months

Patient case

HCV suppression and clinical improvement in Child A case

***1954, male, 82kg**

HCV GT 4, comp. cirrhosis, past HCC, Child A

▶ SVR after re-treatment with SMV/SOF + RBV

